New Delhi, India: Dr. Krishna Ella, the founder and managing director of Bharat Biotech, said on Wednesday that six months after receiving the second dosage of a coronavirus vaccination is the best time for a booster dose. However, he noted that the government would make the final choice.

He said the Phase 2 trials for the nasal vaccine being produced by Bharat Biotech after its Coavaxin were completed and data was being analysed. Ella suggested that the nasal Covid vaccine may be used in place of the second dosage of Covaxin, or to protect people who had already been sick. In comparison to an injectable vaccination that does not reach the upper lungs, the nasal vaccine was more successful in avoiding illness, he said, and could eliminate the need for a vaccinated person to continue wearing the mask.

Bharat Biotech, according to Ella, is the only firm in the world that has conducted clinical trials on children aged 2 to 18. Ella also discussed the difficulties in getting Covaxin approved by the WHO at the Times Now Summit 2021. He stated that they had 5 vaccines that had been pre-qualified by the World Health Organization "So we knew exactly what to do and how to accomplish it. However, there are many unfavourable media individuals who have even written to scientific publications to inquire about a death in Bhopal. It happened as a result of suicide, but the vaccine was attributed ".

Health: The bill to fluoridate drinking water has passed its third reading

Vaccine Milestone: Over 109 cr doses administered in country so far: Mandaviya

Indonesia to begin giving Covid booster doses, post 50-pc populace fully inoculated